NYSEHealth CareHealth Care ServicesS&P SmallCap 600
$36.19
-11.23 (-23.68%)
Close of Nov 06, 2026 · end-of-day data
AMN 8-K filings in 2025
Every material Form 8-K Amn Healthcare Services filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
AMN Healthcare reported third quarter 2025 revenue of $634.5 million, down 8% from a year earlier, and GAAP net income of $29.3 million, or $0.76 per diluted share, versus $0.18 a year earlier. GAAP profit included a $39.2 million gain on the sale of Smart Square, and adjusted diluted EPS fell 36% to $0.39, so shareholders face a mixed picture. The company guided fourth quarter revenue to $715 million to $730 million, 1% to 3% below the prior year.
Q3 2025 revenue $634.5 million, down 8% year over year; adjusted EBITDA $57.5 million, down 22%
GAAP diluted EPS $0.76 versus $0.18 a year earlier; adjusted diluted EPS $0.39 versus $0.61
Q3 income from operations included a $39.2 million gain on the sale of Smart Square
Q4 2025 guidance: revenue $715 million to $730 million, 1% to 3% lower than the prior year
AMN Healthcare completed a $400.0 million offering of 6.500% senior notes due 2031 and amended its credit agreement on October 6, 2025. The company expects to use the notes proceeds, approximately $100.0 million of revolver borrowings and cash on hand to redeem its $500.0 million of 2027 notes on October 22, 2025. The amendment cuts the secured revolving facility to $450.0 million from $750.0 million and extends its maturity to October 6, 2030, which reshapes the company's debt maturities and borrowing capacity for shareholders.
$400.0 million of 6.500% senior notes due January 15, 2031 issued by AMN Healthcare, Inc., with interest payable semi-annually starting July 15, 2026
Expected redemption of all $500.0 million of 2027 notes on October 22, 2025, funded by the new notes, about $100.0 million of revolver borrowings and cash on hand
Secured revolving credit facility reduced to $450.0 million from $750.0 million and extended to October 6, 2030 from February 2028
Net leverage ratio covenant set at no greater than 5.25 to 1.00 through March 31, 2027, stepping down to 5.00 to 1.00 and then 4.75 to 1.00 after June 30, 2028
AMN Healthcare reported second-quarter 2025 revenue of $658 million, down 11% from a year earlier, and a net loss of $116.2 million, or $3.02 per diluted share, after $128 million in noncash goodwill and intangible asset impairment charges. Management said clients slowed decision-making amid an uncertain healthcare policy environment, and third-quarter revenue guidance of $610 million to $625 million is 9% to 11% below the prior year, so shareholders face both a sharp profit decline and a weaker near-term revenue outlook.
Q2 2025 revenue was $658 million, down 11% from $740.7 million in Q2 2024.
Net loss was $116.2 million, or $3.02 per diluted share, versus net income of $16.2 million, or $0.42 per diluted share, a year earlier.
Adjusted diluted EPS was $0.30, compared with $0.98 in the second quarter of 2024.
Third-quarter 2025 revenue is guided to $610 million to $625 million, 9% to 11% lower than the prior year.
AMN Healthcare reported first-quarter 2025 revenue of $690 million, down 16% from a year earlier, and a net loss of $1 million, or $0.03 per diluted share, compared with net income of $17 million, or $0.45 per share, in the first quarter of 2024. Adjusted diluted EPS fell to $0.45 from $0.97, and second-quarter revenue guidance of $645 million to $660 million points to a further decline of 11% to 13% from the prior year, which weighs on the outlook for shareholders.
Q1 2025 revenue was $690 million, down 16% year over year and 6% sequentially; gross margin was 28.7%, down 270 basis points year over year.
Net loss was $1 million, or ($0.03) per diluted share, versus net income of $17 million, or $0.45 per share, in Q1 2024.
Second-quarter 2025 revenue guidance is $645 million to $660 million, 11% to 13% lower than the prior year.
Cash flow from operations was $93 million in the first quarter, and the company reduced debt by $60 million.
At its May 2, 2025 annual meeting, AMN Healthcare shareholders approved the AMN Healthcare 2025 Equity Plan and elected all nine director nominees. They also rejected a shareholder proposal on special shareholder meetings and approved KPMG LLP as auditor for fiscal 2025. The votes set the terms for future equity compensation and governance, and the filing reports no change in company finances.
Equity Plan approved: 28,953,916 for, 849,838 against, 12,447 abstentions
Shareholder proposal on special shareholder meetings not approved: 1,976,787 for, 27,818,286 against
Advisory vote on named executive officer pay approved: 23,059,546 for, 6,703,892 against
KPMG LLP ratified as independent auditor for fiscal year ending December 31, 2025: 31,606,644 for
AMN Healthcare reported fourth quarter 2024 revenue of $735 million, down 10% from a year earlier, and a net loss of $188 million, or $4.90 per diluted share, driven by a $222 million non-cash goodwill impairment. The company also guided first quarter 2025 revenue to $660 million to $680 million, which it said is 17% to 20% lower than the year-ago period.
Q4 2024 revenue was $735 million, down 10% year over year; full year 2024 revenue was $2.98 billion, down 21%.
Q4 2024 GAAP net loss was $188 million ($4.90 per diluted share), versus net income of $12 million a year earlier, due to a $222 million goodwill impairment.
Adjusted diluted EPS was $0.75 in Q4 2024, compared with $1.32 a year earlier.
First quarter 2025 guidance calls for consolidated revenue of $660 million to $680 million and an adjusted EBITDA margin of 7.7% to 8.2%.
AMN Healthcare's Chairman of the Board, Douglas D. Wheat, retired from the board effective immediately, as notified on February 4, 2025. The company said the retirement was not due to any disagreement with the company or board on operations, policies or practices. Mark G. Foletta was appointed Chairman of the Board, and Wheat was named Chairman Emeritus.
Douglas D. Wheat notified the company on February 4, 2025 of his retirement from the board, effective immediately
Wheat was designated Chairman Emeritus of the Board upon retirement
Mark G. Foletta was appointed Chairman of the Board
The filing states Wheat's retirement was not due to any disagreement with the company or board
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Amn Healthcare Services filing is on SEC EDGAR ↗. 8-K briefs of other companies →